IAIrene Pachon Angona

Irene Pachon Angona

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irene Pachon Angona has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Gisbert Schneider

    ETH Zurich

    4 shared publications
  • Jan A. Hiss

    Department of Biosystems Science and Engineering, Molecular Design Laboratory, ETH Zurich, Klingelbergstrasse 48, Basel, Switzerland, 4056

    2 shared publications
  • Kenneth Atz

    Roche Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel, Switzerland, 4070

    2 shared publications
  • Leandro Cotos

    ETH Zurich, Department of Chemistry and Applied Biosciences, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland

    2 shared publications
  • Achi Haider

    Roche Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel, Switzerland, 4070

    1 shared publication
  • Bernard Refouvelet

    Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive (UR-LINC / EA481) – Groupe Chimie Médicinale Université de Bourgogne Franche-Comté UFR Santé 19 rue Ambroise Paré Besançon 25000 France

    1 shared publication

Latest Publications

  • Open Access

    Learning from Nature: De novo Generative Design of Natural-Product-Inspired Opioid Agonists

    by Manuel G. Schriefer Treiber, Bryce D. Delgado, Joy Becher, Przemysław Dutka, Mattis Hilleke, Irene Pachon Angona, Josefa Dela Cruz-Chuh, Shu Ti, Laëtitia Comps-Agrar, Petra Schneider, et al.

    Developing safe and potent analgesics remains a critical global public health priority. Here, we show that generative de novo design can rapidly deliver novel opioid receptor agonists with high synthetic accessibility and desirable pharmacology. Inspired by the natural product mitragynine pseudoindoxyl, a complex metabolite found in traditional medicinal Kratom leaves, we leveraged its µ-opioid receptor binding characteristics to guide our generative computational framework. This deep learning approach successfully translated the partial agonism of the natural product and its G protein signaling bias into novel, structurally distinct chemotypes. One-third of the synthesized compounds exhibited potent receptor activation. Without requiring optimization, lead designs showed favorable pharmacokinetics, minimal off-target activity, and no β-arrestin recruitment. Cryogenic electron microscopy confirmed orthosteric receptor engagement, revealing that sub-pocket interactions alone do not account for their signaling behavior. By shifting away from stochastic high-throughput screening, this nature-inspired, artificial intelligence-driven workflow compresses discovery timelines while maximizing hit rates and molecular quality to deliver next-generation therapeutics.

  • Open Access

    Selective inhibition of Mycobacterium tuberculosis GpsI unveils a novel strategy to target the RNA metabolism

    by Tizian Griesser, Rui Wang, Irene Pachon Angona, Janis Rogenmoser, Julia Obrist, Gisbert Schneider, Peter Sander

    Polyribonucleotide nucleotidyl-transferases (PNPases) play a critical role in the degradation of mRNA. The mycobacterial PNPase, guanosine penta-phosphate synthase I (GpsI), is an essential enzyme in Mycobacterium tuberculosis (Mtb), collaborating with endoribonucleases and helicases to process RNA. In this study, we identify GpsI as a novel and underexplored drug target. The inhibitor 1-(4′-(2-phenyl-5-(trifluoromethyl) oxazole-4-carboxamido)-[1,1′-biphenyl]-4-caroxamido) cyclopentane-1-carboxylic acid (X1), discovered through a whole-cell screening, specifically inhibits GpsI activity in biochemical assays. Biochemical and physiological analyses of engineered GpsI variants and recombinant Mycobacterium smegmatis pinpoint amino acids 328 and 527 as critical residues for the selective activity of X1 against Mtb complex. High-resolution cryo-electron microscopy analysis of the ternary GpsI–X1–poly(A) complex elucidates the drug-binding pocket, providing insight into its mechanism of action. This study introduces a potent inhibitor targeting the underexplored Mtb-GpsI and offers a molecular explanation for its selective specificity.


  • Open Access

    Combining de novo molecular design with semiempirical protein–ligand binding free energy calculation

    by Michael Iff, Kenneth Atz, Clemens Isert, Irene Pachon-Angona, Leandro Cotos, Mattis Hilleke, Jan A. Hiss, Gisbert Schneider

    Semi-empirical quantum chemistry methods estimate the binding free energies of de novo generated ligand–protein complexes.


  • Top Cited Papers
    Open Access

    Leveraging molecular structure and bioactivity with chemical language models for de novo drug design

    by Michael Moret, Irene Pachon Angona, Leandro Cotos, Shen Yan, Kenneth Atz, Cyrill Brunner, Martin Baumgartner, Francesca Grisoni, Gisbert Schneider

    Generative chemical language models (CLMs) can be used for de novo molecular structure generation by learning from a textual representation of molecules. Here, we show that hybrid CLMs can additionally leverage the bioactivity information available for the training compounds. To computationally design ligands of phosphoinositide 3-kinase gamma (PI3Kγ), a collection of virtual molecules was created with a generative CLM. This virtual compound library was refined using a CLM-based classifier for bioactivity prediction. This second hybrid CLM was pretrained with patented molecular structures and fine-tuned with known PI3Kγ ligands. Several of the computer-generated molecular designs were commercially available, enabling fast prescreening and preliminary experimental validation. A new PI3Kγ ligand with sub-micromolar activity was identified, highlighting the method’s scaffold-hopping potential. Chemical synthesis and biochemical testing of two of the top-ranked de novo designed molecules and their derivatives corroborated the model’s ability to generate PI3Kγ ligands with medium to low nanomolar activity for hit-to-lead expansion. The most potent compounds led to pronounced inhibition of PI3K-dependent Akt phosphorylation in a medulloblastoma cell model, demonstrating efficacy of PI3Kγ ligands in PI3K/Akt pathway repression in human tumor cells. The results positively advocate hybrid CLMs for virtual compound screening and activity-focused molecular design.


  • Multicomponent Reactions As a Privileged Tool for Multitarget-Directed Ligand Strategies in Alzheimer’s Disease Therapy

    by Sylvain Grosjean, Irene Pachón-Angona, Michella Dawra, Bernard Refouvelet, Lhassane Ismaili

    Among neurodegenerative pathologies affecting the older population, Alzheimer’s disease is the most common type of dementia and leads to neurocognitive and behavioral disorders. It is a complex and... Graphical abstract